Mankind Pharma Q4 Profit Rises 30 Percent on Chronic Care
Mankind Pharma reported a 30 percent rise in fourth-quarter profit to 5.54 billion rupees. Growth was led by demand for chronic and consumer health products.
Xurve View
洞察:
Xurve View
MANKIND PHARMA LTD reported a 30% rise in fourth-quarter profit to 5.54 billion rupees ($57.39 million) on Tuesday, up from 4.25 billion rupees a year earlier. The company saw revenue climb 12% to 34.43 billion rupees for the quarter ended March 31. Strong domestic demand for chronic treatments allows Mankind to outperform peers struggling with pricing pressure in the United States.
